종근당홀딩스

001630KOSPI의약품 제조업

66.9 / 100

Reference Date: 2026-07-24

Financial Score31.5 / 40

News Sentiment19.4 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PER is significantly undervalued vs. peers but Revenue metrics are weak. Slightly up 2.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

JonggeunDang Holdings became a holding company through a corporate split in 2013, owning key subsidiaries such as JonggeunDang, Kyungbo Pharmaceuticals, and JonggeunDang Bio. Its primary revenue streams include management fees, brand usage fees, and dividends, with a strategy focused on specialized business areas to enhance corporate and shareholder value. Major subsidiaries operate in diverse sectors like raw pharmaceutical materials, finished drugs, and health functional foods.

Number of Employees

38people

Average Salary

143.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

4.60Industry Average 11.238.0Point

Half of industry avg (excellent)

PBR

0.21Industry Average 0.817.0Point

Half of industry avg (excellent)

ROE

6.16Industry Average 4.015.5Point

1.5x industry avg (good)

Debt Ratio

10.95Industry Average 12.434.0Point

In line with industry avg

Trend 2023~20257.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲4.5% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲86.5% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 5.3% (improving, 3yr)

Detailed News Sentiment

6 totalPositive 5Neutral 1Negative 0Average Sentiment Score 77.5

Positive
종근당, 연구개발 전문 뉴라테온 설립...기술 중심 혁신 집중
종근당이 기술 중심 혁신을 위한 자회사 설립으로 경쟁력 강화를 추진, 긍정적 시장 반응 예상.
Positive
종근당, 연구개발 전문회사 '뉴라테온' 출범…원동한 대표 선임
종근당의 신규 연구개발 전문 자회사 '뉴라테온' 출범으로 혁신 역량 강화 및 시장 경쟁력 향상 기대.
Positive
[BIO USA 2026] 아리바이오, 푸싱 이후 다음 파트너링 시동
아리바이오의 푸싱제약과의 대규모 기술이전 계약 이후 새로운 파트너십 구축으로 긍정적인 시장 반응 예상.

Detailed Momentum

52-week position1.0Point

Near 52w low (14%, downtrend)

Current 39,100Won52-week high 53,70052-week low 36,700

1-month return4.0Point

1m +2.76% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral투자설명서2026-07-01
Neutral효력발생안내( 2026.6.19. 제출 증권신고서(채무증권) )2026-07-01
Neutral증권발행실적보고서2026-07-01
Neutral[발행조건확정]증권신고서(채무증권)2026-06-30
Neutral지속가능경영보고서등관련사항(자율공시)2026-06-30